Swiss Medtech Firm Aesyra Secures Series A Funding to Advance Non-Invasive Dental Device for Bruxism Treatment

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 26, local time in Switzerland, medical device company Aesyra completed its Series A financing round, led by VitaTech. The funds raised will be used to support the development of oral sensors for the treatment of bruxism and to accelerate the product’s commercialization.

Aesyra, founded in November 2017 and headquartered in the Canton of Vaud, Switzerland, is a medical device company dedicated to developing intraoral sensors for dental professionals to treat dental and sleep-related disorders.

Bruxism, also known as teeth grinding, affects up to 30% of adults. It is characterized by clenching or grinding teeth during sleep, which can easily lead to problems such as sleep disturbances, facial pain, headaches, muscle tension, and dental damage. Furthermore, in patients who have undergone dental implant surgery, the presence of bruxism can result in damage to the implants.

Traditional treatment involves fabricating dental splints for patients to protect their teeth. However, these splints do not alleviate bruxism symptoms; consequently, patients wearing dental splints continue to experience issues such as facial pain and muscle tension.

Aesyra’s flagship product, AesyBite, is the first dental device capable of monitoring and reducing bruxism symptoms. It features the following advantages: (1) Utilization of biofeedback therapy. AesyBite adapts and adjusts intraoral treatment protocols based on individual patients’ biological responses, reducing bruxism symptoms by over 70%; (2) Monitoring of bruxism and tracking of treatment progress. Throughout the treatment cycle, AesyBite dynamically adjusts the treatment plan via physiological feedback according to the patient’s recovery status, providing the most appropriate therapeutic mode during different treatment phases; (3) Protection of teeth and oral implants. As mentioned above, conventional treatments such as dental splints do not alleviate bruxism symptoms and may even damage teeth and other intraoral implants. AesyBite addresses this limitation by protecting existing dental restorations and implants while treating the condition; (4) Ease of use and comfortable experience.

Marco Letizia, CEO of Aesyra, stated, “We will utilize the funds from this investment to achieve the industrialization of our technology and further advance clinical studies, striving to bring our products to market at an early stage to help healthcare professionals better treat dental diseases.”

Paolo Orsatti, Director at VitaTech, added, “We are highly optimistic about Aesyra’s growth potential. The sleep sector is poised to garner significant attention in the future healthcare industry. We believe that through our collaboration with Aesyra, we will be able to create greater value for our shareholders.”

VitaTech is an investment firm funded by the Zambon family and other European ultra-high-net-worth private investors and family offices, focusing on investments in early-stage and growth-stage healthcare companies in Europe. The firm aims to integrate healthcare with technology and has completed two investments to date. VitaTech led a $2.5 million investment round in Gain Therapeutics on February 19, 2019.

(Compiled by Liu Yujing)